Proactive Investors - Run By Investors For Investors

Orgenesis seals pact with Ben-Gurion University to develop dissolvable carriers for cell culturing

Under the license deal, Orgenesis will receive worldwide rights to develop and commercialize technologies utilizing the dissolvable carriers for cell culturing
A researcher in a lab
Orgenesis is focused on the development and manufacture of cell therapies for advanced medicinal products

Orgenesis Inc (NASDAQ:ORGS), a developer and manufacturer of advanced cell therapies, announced Wednesday that it has entered into a licensing and collaboration agreement with Israel-based Ben-Gurion University for the development of dissolvable carriers for cell culturing.

The technology was developed by Professor Smadar Cohen, founder and director of The Regenerative Medicine and Stem Cell (RMSC) Research Center at Ben-Gurion University.

Under the license agreement, the Germantown, Maryland, company has received exclusive, worldwide rights to make, develop and commercialize technologies utilizing the dissolvable carriers for cell culturing. The technology potentially allows Orgenesis to reduce the cost and complexity of manufacturing its cell therapy programs.

READ: Orgenesis teams up with New York Blood Center for US cell therapy development program

“We are honored to continue our strategic partnership with leading scientists at Ben-Gurion University who have developed this unique dissolvable carrier for cell culturing,” said Orgenesis CEO Vered Caplan. “These breakthrough carriers are the basis for our development of an automated adherent cell culturing system allowing seamless seeding, harvesting and passaging of cells in closed bioreactors. We are excited about the potential of this technology and its abilities to advance adherent cell culturing for cell therapies.”

Professor Smadar Cohen said the Regenerative Medicine and Stem Cell Research Center would work with “skilled” scientists at Orgenesis to accelerate research.

“The research and development of resolvable carriers for cells contains the potential to produce higher quality cells and the technology allows dissolving of carriers and automatic seeding of new ones,” said Cohen. “We believe that Orgenesis has developed a highly scalable and cost-effective platform for cell therapies, which could help accelerate the development of this technology,” said Cohen.

Shares in Orgenesis were up 3.9% to $ 5.35 in morning trading in the US.


Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
December 03 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease
lung in x-ray
February 25 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use